Skip to main content

Advertisement

Table 4 Reasons for treatment discontinuation of patients with OS ≥24 versus < 24 months in the axitinib titration arm

From: Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study

Reason for treatment discontinuation, n (%) OS ≥24 months n = 33a OS < 24 months n = 20b
Objective progression or relapse 17 (52) 16 (80)
Adverse event 5 (15) 2 (10)
Death 1 (3) 1 (5)
Global deterioration of health status 0 1 (5)
Patient refusal to continue treatment for reason other than adverse event 1 (3) 0
Total 24 (73) 20 (100)
  1. Abbreviation: OS overall survival
  2. aIncluding 9 patients still on treatment
  3. bExcluded 3 patients who were censored < 24 months in OS